Abstract: Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.

Abstract: A therapeutic agent for solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and to be administered in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination has strong antitumor effect and is therefore useful for treatment of solid cancers.

Abstract: A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.

Abstract: The embodiment of the present disclosure provides a system for co-producing a xylitol and a caramel pigment by utilizing a xylose mother liquid, including an extraction assembly, a refined hydrogenation assembly and a browning reaction assembly. The extraction assembly is configured to obtain an extracted liquid and a raffinate liquid respectively by performing an initial extraction on the xylose mother liquid; the refined hydrogenation assembly is configured to prepare a crystal xylitol by performing a refined hydrogenation process on the extracted liquid; the browning reaction assembly is configured to prepare the caramel pigment by performing a browning reaction process on the raffinate liquid.

Abstract: Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.

Abstract: The present invention provides an inhalation spray of Semaglutide with good patient compliance and high bioavailability at the targeted site, which belongs to the technical field of pharmaceutical preparation. The inhalation spray of Semaglutide according to the invention comprising, by weight to volume, 0.01% to 20% of Semaglutide in the inhalation spray, wherein the proportion of fine particles with a particle size less than 5 ?m formed after the inhalation spray is atomized by a spray device is not less than 10%. The inhalation spray of Semaglutide according to the invention has a simple formulation, low toxic and side effects, atomization administration of the medicinal liquid through an inhalation device, uniform distribution of spray droplets, a high lung deposition rate, low irritation and convenient administration, which is suitable for industrial production. The invention further provides a preparation method of the inhalation spray of Semaglutide.

Abstract: The present disclosure provides suspendable ophthalmic solutions with excellent redispersibility. The present disclosure provides an aqueous suspension agent comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, and a nonionic surfactant.

Abstract: Provided is a microneedle patch which is easily to be applied on a skin surface. One or more holes are provided inside a protective sheet of the microneedle patch, and one or more cutting lines running from an outer edge of the protective sheet toward the holes are also provided. The cutting lines may be symmetrically arranged on both sides of the hole. Providing an incision on the outer edge of the cutting lines of the protective release sheet facilitates cutting along the cutting lines. In the use of the microneedle patch, both sides of the cutting line of the protective release sheet are held and torn so as to bring out a microneedle array adhesive sheet and apply it on a skin. Then the microneedle array surface is slightly compressed, thereby the microneedle is inserted into the stratum corneum.

Abstract: Disclosed are a software for analyzing images of a fertilized egg, the software providing a means for executing a process including: (a) a step of measuring the difference in area between the female pronucleus and the male pronucleus from images of a fertilized egg obtained in a period of 1 to 10 hours before the time of occurrence of male and female pronuclear membrane breakdown as a reference; (b) a step of measuring the difference in are between the female pronucleus and the male pronucleus from images of the fertilized egg obtained immediately before the time of occurrence of male and female pronuclear membrane breakdown as the reference; and (c) a step of storing the measured values of the area difference obtained in the step (a) and the area difference obtained in the step (b), to be readable at any time as needed, and an apparatus incorporating this software.

Abstract: The present invention provides alginic acid derivatives represented by formula (1) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (1) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.

Abstract: An edged cataplasm and a manufacturing process are disclosed. The edged cataplasm includes a support layer; a drug layer, which adheres to the bottom of the support layer; a cross-type release film, which adheres to the bottom of the drug layer. The cross-type release film includes a first-release film piece and a second-release film piece, and the adjacent edges of the first-release film piece and the second-release film piece are partially overlapped. In addition, the edged cataplasm further includes a waterproof-breathable adhesive layer, which adheres to the top of the support layer and coated with silver ions or a nano antibiotic layer; a polyethylene terephthalate (PET) film, which adheres to the top of the waterproof-breathable adhesive layer. The PET film includes a first part and a second part, and the adjacent edges of the first part and the second part are arranged as an aligned S-shaped edge.

Abstract: There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic ? cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

Abstract: The present invention relates to a crystalline form and/or maleate, phosphate, L-tartrate, and adipate of the compound represented by the structural formula I, and various crystalline forms of various salt forms, and preparation methods and applications thereof.

Abstract: The present disclosure discloses an expectorant compound, and specifically discloses compounds represented by formula I and formula II, pharmaceutically acceptable salts or tautomers thereof.

Abstract: A composition applied to preparation of a medicament for treating cerebrovascular diseases, in particular ischemic cerebrovascular diseases. The composition contains 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof and borneol. By means of the compatibility between 2-amino-6-trifluoromethoxybenzothiazole and d-borneol, according to non-clinical cell test and animal efficacy test results, for cerebrovascular diseases, 2-amino-6-trifluoromethoxybenzothiazole and d-borneol have the effect of synergistically increasing efficacy.

Abstract: The present application provides use of Compound (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof in manufacture of a medicament useful in treating a disease related to high expression or abnormal activation of JAK and SYK kinases, comprising an autoimmune disease, such as an immune-mediated skin disease, in particular psoriasis, atopic dermatitis and SLE. Compound (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention can improve the skin lesions in mice with psoriasis, atopic dermatitis and SLE, alleviate the injury of kidney, inhibit the expansion of immune organs, reduce the level of inflammation, inhibit the increase of SLE related antibodies and cytokines in serum, and has a certain safe therapeutic window, which has a good clinical application prospect.

Abstract: Disclosed is a stable aqueous pharmaceutical composition or lyophilized pharmaceutical composition comprising a protein as the active ingredient. The pharmaceutical composition comprises a protein having physiological activity and two different nonionic surfactants, including polysorbate 80 and polyoxyethylene(160) polyoxypropylene(30) glycol as the nonionic surfactants, for example, and as optional components, sodium chloride as a neutral salt, sucrose as a disaccharide and citrate buffer as a buffering agent.

Abstract: A method of treating a subject with cholangiocarcinoma having a co-occurring genetic alteration in FGFR2 and a cancer driver gene selected from TP53, BAP1, ARID1A, MLL2, PIK3C2B, IKBKE, MCL1, MDM4, and MYC, whereby the subject is administered (S)-1-[(3)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof.

Abstract: A stable pharmaceutical composition containing a non-steroidal anti-inflammatory drug derivative, at least comprising a separated solid part and liquid part, the solid part comprising a therapeutically effective dose of non-steroidal anti-inflammatory drug derivative and the liquid part being a pharmaceutically acceptable solvent.

Abstract: The embodiment of the present disclosure provides a method for crystallizing compound sugar solution of xylose and sucrose, including: introducing a mixed solution of sucrose crystals, xylose crystals and water into a crystallization device, setting a stirring speed in a range of 60 rpm-120 rpm, a temperature in a range of 75° C.-80° C., a vacuum pump pressure in a range of 50 mbar-200 mbar, evaporating the mixed solution until a Brix value of the mixed solution reaches a range of 78 Brix-81 Brix, and stopping the vacuum evaporation, adjusting the temperature to a range of 70° C.-75° C., dropwise adding food-grade isopropanol solution or ethanol solution to the evaporated mixed solution, adding sucrose seed crystals, and continuing stirring to obtain a solution, when small seed crystals grow in the solution, dropping the temperature to a range of 40° C.-60° C. at a rate of 10° C./h, and then stirring for 6 h to obtain the mixed sugar solution; centrifuging and drying at 40° C.-60° C.